tomaralimab   Click here for help

GtoPdb Ligand ID: 9408

Synonyms: OPN-305 | OPN305 | VK5A/H4
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tomaralimab (OPN305) is a first-in-class humanised monoclonal antibody against Toll-like receptor 2 (TLR2) being developed by Opsona Therapeutics. It is being investigated for potential clinical use in certain hematological and immunological conditions. OPN305 and its possible uses are claimed in patent WO2011003925 [4]. The effect of TLR2 antagonism on myocardial ischemia/reperfusion injury in a large animal model (pigs) is reported in [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Arslan F, Houtgraaf JH, Keogh B, Kazemi K, de Jong R, McCormack WJ, O'Neill LA, McGuirk P, Timmers L, Smeets MB et al.. (2012)
Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs.
Circ Cardiovasc Interv, 5 (2): 279-87. [PMID:22354933]
2. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G et al.. (2010)
Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody.
Circulation, 121 (1): 80-90. [PMID:20026776]
3. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. (2006)
Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response.
Cardiovasc Res, 72 (3): 384-93. [PMID:17054926]
4. Dellacasagrande J. (2011)
Humanised antibodies to toll-like receptor 2 and uses thereof.
Patent number: WO2011003925. Assignee: Opsona Therapeutics Limited. Priority date: 06/07/2009. Publication date: 13/01/2011.
5. Farrar CA, Keogh B, McCormack W, O'Shaughnessy A, Parker A, Reilly M, Sacks SH. (2012)
Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury.
FASEB J, 26 (2): 799-807. [PMID:22042224]
6. Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, Richard V. (2007)
Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction.
Arterioscler Thromb Vasc Biol, 27 (5): 1064-71. [PMID:17332486]